Huasen Pharmaceutical

Chongqing Huasen Pharmaceutical Co., Ltd. (stock abbreviation: Huasen Pharmaceutical, stock code: 002907) is a national key high-tech enterprise integrating drug research and development, production, and sales, and an A-share listed company on the Shenzhen Stock Exchange. Over the years, the company has been honored as a National Enterprise Technology Center, a National Advanced Private Enterprise for Employment and Social Security, a Quality Award for Healthy China, a China Patent Award, one of the Top 100 Chinese OTC Enterprises in 2019, a Benchmark Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of New China, a National Enterprise Honoring Contracts and Keeping Promises, a National Intellectual Property Demonstration Enterprise, and an Advanced Grassroots Party Organization in Chongqing. It has also established a Postdoctoral Research Workstation and a Chongqing Hai Zhi Workstation.
Huasen Pharmaceutical has established Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., Chongqing Huasen Pharmacy Retail Chain Co., Ltd., and Pharscin US Inc. (Huasen Pharmaceutical (USA) Co., Ltd.).
Currently, the company holds 70 drug approval numbers, including traditional Chinese medicines, chemical raw materials, and preparations. Among these, 51 are included in the national medical insurance catalog, 46 national drug standards have been formulated, and 67 patents have been obtained. It has successively undertaken a total of 120 scientific research projects from national, provincial, and municipal ministries and commissions.
Huasen Pharmaceutical is actively positioning itself in the innovative drug sector. It has introduced an international team of scientists, established an innovative drug business division, and is building overall R&D capabilities for innovative drugs. Currently, it has 4 self-developed innovative drug projects for oncology, with potential indications covering tumor immunotherapy and various solid tumors such as lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. The company has built 3 innovative drug platforms at an international level: a platform for bioactivity screening of molecular targeted drugs based on different target types using functional genomics, a platform for structure design and synthesis of small molecule drugs targeting specific targets, and a platform for druggability evaluation, drug metabolism, and pharmacokinetic testing. These platforms endow the company with innovative drug R&D capabilities from drug discovery to preclinical development, achieving breakthroughs from 0 to 1 in innovative drugs.
Huasen Pharmaceutical has established a drug production platform integrating the Internet, big data, and artificial intelligence in Rongchang High-tech Zone, equipped with 22 production lines for tablets, soft capsules, lyophilized powder injections, API synthesis, and traditional Chinese medicine pretreatment and extraction. It has built fully automated intelligent TCM extraction production lines and a modern warehousing and logistics center. The company has fully implemented artificial intelligence systems such as MES, BMS, EMS, SCADA, and DCS, and is currently undergoing FDA certification in the United States, aiming to build an international CDMO production platform. It has been awarded the title of National Intelligent Manufacturing Demonstration Factory, a pilot enterprise for classified and graded cybersecurity management by the Ministry of Industry and Information Technology, and one of the top ten 5G + Industrial Internet pilot demonstration enterprises in Chongqing.
Huasen Pharmaceutical adheres to professional academic promotion, conveying accurate information and services to medical professionals. Currently, its academic network covers 31 provinces, municipalities, and autonomous regions nationwide. In addition, it has established Pharscin US Inc. in the United States to support the company in seeking cooperation opportunities at the forefront of innovative drugs in Europe and the United States.
Huasen Pharmaceutical actively fulfills its social responsibilities. Adopting a model of "company + research institutes + farmers," it has established standardized planting bases for traditional Chinese medicinal materials in Rongchang, Xiushan, and Wanzhou districts of Chongqing, participating in targeted poverty alleviation and helping local farmers increase income. During the COVID-19 pandemic, the company donated medicines and medical protective materials to frontline areas such as Wuhan, exceeding 2 million yuan. In the aftermath of the 5.12 Wenchuan earthquake and the 4.20 Ya'an earthquake, Huasen people were active in every public welfare scene. The company has successively received honors such as "Caring Unit," "Advanced Private Enterprise in Chongqing for COVID-19 Response," and "Advanced Private Enterprise in the 'Ten Thousand Enterprises Assisting Ten Thousand Villages' Targeted Poverty Alleviation Campaign."
Huasen Pharmaceutical regards talent as the most important resource for corporate development. It adheres to a talent strategy of "putting people first and achieving employee success," providing comprehensive training and various welfare and insurance systems, and offering sustainable development space for employees. At the same time, the company fosters a corporate culture of "Huasen is my home," enhancing employees' sense of belonging and initiative, and contributing to their happiness.
Huasen Pharmaceutical takes as its corporate mission "developing good medicines, promoting human health, and achieving employee success," adhering to the values of "integrity, diligence, gratitude, learning, teamwork, and innovation." With firm steps, it strives for the Huasen dream of "being an international pharmaceutical enterprise, making no disease difficult to cure," contributing to the construction of the Chengdu-Chongqing economic circle and realizing the Chinese Dream of national rejuvenation.

Employment Principles:
Huasen adheres to the principle of fair, just, and open talent selection and appointment. It has established a scientific human resource management system so that every capable and ambitious individual can fully develop their abilities in the construction of Huasen and realize their aspirations.
"Three ways to retain people" is the core orientation of Huasen's human resource management. Huasen creates an excellent platform and development space for employees' career development—retaining them through career opportunities; establishing an incentive-based distribution policy—retaining them through competitive compensation; and advocating the Huasen family culture, continuously strengthening internal affinity and cohesion—retaining them through culture.
We look forward to more people joining Huasen and more attention to Huasen's development!